Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.59 |
| ▸ | SYK | P43405 | 12/20 | 0.57 |
| ▸ | WEE1 | P30291 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 4/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCND2 | P30279 | 1/20 | 0.51 |
| ▸ | CCND3 | P30281 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230101 | 0.89 | BRAF (0.50) | ALKSYK | |
| SCHEMBL5501445 | 0.88 | MAP4K1 (0.64) | ALKWEE1EGFRCDK4CCND1 | |
| SCHEMBL226380 | 0.85 | STK17A (0.58) | WEE1CDK4CCND1CCND2CCND3 | |
| SCHEMBL29372589 | 0.82 | ALK (0.67) | ALKSYKWEE1EGFRCDK4 | |
| SCHEMBL29575961 | 0.79 | ALK (0.64) | ALKSYKWEE1EGFRCDK4 | |
| SCHEMBL2573809 | 0.79 | YES1 (0.53) | — | |
| SCHEMBL2573807 | 0.79 | SRC (0.53) | WEE1 | |
| SCHEMBL16513440 | 0.76 | EGFR (0.79) | SYKEGFR | |
| SCHEMBL29847452 | 0.76 | EGFR (0.79) | SYKEGFR | |
| SCHEMBL5497607 | 0.76 | LCK (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | claimed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | claimed |
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | MAP3K5, MAP3K1, MAP3K2 | ALK 2550/4885SYK 1282/4885WEE1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.